Interferential electrical and topical non-steroidal anti-inflammatory drug synergistic training injury sub-phase rehabilitation method

Abstract

This invention provides a phased rehabilitation method for training injuries that combines interferential current with topical nonsteroidal anti-inflammatory drugs (NSAIDs), relating to the fields of sports medicine, physical therapy, and rehabilitation medicine. It includes: injury assessment and classification, phased initial parameter setting, synergistic treatment of drug application penetration and interferential current field-enhanced penetration, dynamic adjustment of objective indicators, and multi-dimensional efficacy evaluation. This invention sets differentiated modulation frequencies based on acute injury, chronic strain, and postoperative rehabilitation, utilizing an alternating interferential current field to increase the percutaneous penetration depth and concentration of topical NSAIDs, achieving synergistic enhancement of the target area effect between electrical stimulation analgesia and drug anti-inflammatory effects; and triggers parameter switching with quantitative indicators such as ultrasound, temperature, and electromyography to form an adaptive and precise rehabilitation system. This invention solves the problems of fixed parameters, insufficient drug penetration, and lack of dynamic control in traditional methods, and has the advantages of good efficacy, strong adaptability, and standardization, making it suitable for rapid rehabilitation treatment of various training injuries.

Description

Technical Field

[0001] This invention relates to the fields of sports medicine, physical therapy and rehabilitation medicine, and in particular, to a systematic rehabilitation treatment technology for training injuries that combines mid-frequency interferential electrical physical stimulation, targeted penetration of topical nonsteroidal anti-inflammatory drugs, staged pathological adaptation and dynamic control of objective indicators; more specifically, it relates to a staged rehabilitation method for training injuries that synergistically combines interferential current and topical nonsteroidal anti-inflammatory drugs. Background Technology

[0002] Training injuries have become a major problem affecting the health and athletic ability of trainees in military training, competitive sports, and daily fitness activities. The main types of training injuries are acute soft tissue injuries, chronic strain injuries, and postoperative functional impairments. The main clinical treatment needs focus on rapid pain relief, reduction of edema, promotion of tissue repair, and restoration of motor function.

[0003] Interferential Current Therapy (IFC) is a mainstream clinical physical therapy method widely used in the fields of chronic pain management and sports injury rehabilitation. It involves applying two medium-frequency alternating currents (usually in the range of 2000Hz to 5000Hz) to the human body in a cross-flow manner to form an endogenous low-frequency electric field. The two currents superimpose deep in the tissue to form a low-frequency interference current (1Hz to 150Hz) with a frequency equal to the difference between the two carrier frequencies.

[0004] This low-frequency interfering current can stimulate A-β nerve fibers, activate the spinal cord gate control mechanism to block pain signal transmission, or promote the release of endorphins to exert an endogenous analgesic effect; at the same time, it improves local blood circulation, promotes the clearance of inflammatory metabolites and tissue repair. Compared with direct low-frequency electrotherapy, interfering electrotherapy has the advantages of greater penetration depth, lower skin electrode-skin impedance, and better patient tolerance.

[0005] However, existing interferential electrotherapy still has the following drawbacks in its application to rehabilitation treatment of training injuries:

[0006] 1. Existing interference devices and clinical treatment plans mostly use empirical fixed frequency combinations, lacking differentiated parameter schemes for different pathological stages of acute injuries (such as muscle strains and ligament sprains) and chronic strains (such as chronic tendinitis and fatigue periostitis), which makes it impossible to achieve optimal treatment for each stage of physiological state.

[0007] 2. Sports injury rehabilitation involves different stages, including the inflammation resolution period, tissue repair period, and functional reconstruction period, with significant differences in treatment goals and optimal parameters at each stage. Current technologies lack a systematic and dynamic rehabilitation mechanism that dynamically adjusts interference electrical parameters and medication regimens based on quantifiable objective indicators, making it impossible for treatment plans to adaptively adjust with the rehabilitation process.

[0008] 3. Existing treatment plans mainly rely on subjective scores such as the Visual Analogue Scale (VAS) as the basis for judging efficacy. They lack a systematic method to incorporate objective quantitative indicators such as ultrasound imaging and body surface temperature into the decision-making of treatment parameters. The efficacy evaluation dimension is too single, which restricts the realization of personalized and precise treatment.

[0009] Topical nonsteroidal anti-inflammatory drugs (NSAIDs), such as diclofenac diethylamine cream and transdermal patches, exert local anti-inflammatory and analgesic effects by inhibiting cyclooxygenases (COX-1 / COX-2) in the arachidonic acid metabolic pathway, thereby reducing prostaglandin synthesis. Topical preparations are characterized by strong targeting and minimal systemic side effects.

[0010] However, the percutaneous penetration of topical drugs is limited by the skin's stratum corneum barrier, resulting in low concentrations of drug molecules reaching deep target tissues, limited depth of action, relatively limited bioavailability, and slow onset of action.

[0011] Currently, there have been clinical trials combining physical therapy with topical medications. The clinical application of extracorporeal shock wave therapy combined with topical diclofenac has been reported in the literature (e.g., a clinical study of shock wave therapy combined with diclofenac emulsion for the treatment of chronic Achilles tendinitis). There are also clinical practices combining interferential electrotherapy with exercise rehabilitation training.

[0012] However, existing combined solutions mostly focus on the combination of shockwave, ultrasound, and topical medications. Shockwave therapy and electrotherapy operate on different physical principles. Shockwaves are mechanical waves that do not generate a continuous alternating electric field, lacking a sustained electric field-promoting effect and thus failing to produce a continuous electric field effect that promotes transdermal drug penetration. While ultrasound can enhance penetration, its effect is superficial and its focused area is small, making it difficult to cover large areas of damage. None of these solutions can replace the deep cross-field and long-lasting penetration-promoting advantages of electrotherapy. Furthermore, existing solutions lack a dynamic parameter adjustment system based on objective indicators such as ultrasound imaging, surface infrared thermography, surface electromyography, and joint function, failing to achieve phased, differentiated, and individualized precise rehabilitation. Summary of the Invention

[0013] Therefore, the purpose of this invention is to propose a phased rehabilitation method for training injuries that combines interferential current therapy with topical nonsteroidal anti-inflammatory drugs (NSAIDs). This method combines interferential current therapy with topical NSAIDs, and uses phased, dynamic parameter control based on the injury type and rehabilitation process to achieve synergistic effects between physical therapy and drug therapy. It achieves precise phased adaptation and dynamic parameter control, thereby improving the efficiency and effectiveness of training injury rehabilitation. Breaking through the limitations of traditional single treatments, this method achieves deep synergy between interferential current therapy and topical NSAIDs, adapting to different injury types and rehabilitation stages, and using closed-loop control based on objective indicators. It covers all scenarios, including acute, chronic, and postoperative conditions, to improve rehabilitation outcomes, shorten the rehabilitation cycle, reduce recurrence rates, and enhance clinical standardization.

[0014] This invention provides a phased rehabilitation method for training injuries using interferential current combined with topical nonsteroidal anti-inflammatory drugs, comprising the following steps:

[0015] S1. Baseline assessment and classification of injury: Physical examination, pain score (VAS / NRS), imaging examination (ultrasound / MRI, to check edema area, tissue thickness, and fluid volume), and measurement of local physiological indicators are performed on the patient to classify the injury into three categories: acute soft tissue injury, chronic overuse injury, and postoperative rehabilitation injury.

[0016] This invention establishes a complete treatment system that incorporates three scenarios—acute soft tissue injury, chronic overuse injury, and postoperative rehabilitation injury—into a unified, phased framework. This unified treatment framework covers all scenarios, including acute, chronic, and postoperative conditions, and has good clinical applicability.

[0017] S2. Initial parameter settings in stages: Based on the type of injury and the pathological stage, the carrier frequency, modulation frequency, current intensity of the interference current, as well as the dosage form, single dose, and frequency of use of the topical nonsteroidal anti-inflammatory drug are set differently.

[0018] Preferably, the carrier frequency of the interference current is 2000Hz–6000Hz, the modulation frequency is 1Hz–150Hz, the current intensity is 5mA–30mA, and the single treatment time is 15min–30min.

[0019] Intermediate-frequency alternating electric fields can alter the lipid arrangement of the stratum corneum, opening hydrophilic channels and significantly increasing the transdermal penetration rate and depth of charged drug molecules. The cross-electric field generated by the interference itself naturally possesses the physical basis for driving the penetration of topical nonsteroidal anti-inflammatory drugs.

[0020] Preferably, the topical nonsteroidal anti-inflammatory drug is a cream or transdermal patch containing diclofenac diethylamine, and the concentration of the cream is 1%–2%.

[0021] Specifically, the matching rules between damage type and modulation frequency include:

[0022] For acute soft tissue injuries, the modulation frequency is matched to 80Hz–120Hz, with analgesia as the priority target;

[0023] For chronic overuse injuries, the modulation frequency is matched to 30Hz–80Hz, with tissue repair as the priority target.

[0024] S3. Drug pretreatment and electric field synergistic therapy: First, apply the drug and massage it to allow it to stand to complete the initial penetration. Then, use two sets of electrodes arranged in a cross shape to implement interferential electric therapy. Use the alternating electric field to drive the drug to penetrate deeply and form a physical-drug target synergy.

[0025] Studies have shown that an applied electric field can significantly promote the crossing of charged drug molecules across the stratum corneum barrier through the iontophoresis effect, increasing the amount of drug penetration into deeper tissues. The alternating electric field generated on the skin surface by the mid-frequency alternating current used in interference electrotherapy can change the arrangement structure of the lipid bilayer of the stratum corneum, reduce transdermal permeation resistance, and provide additional penetration driving force for topical drug molecules.

[0026] Specifically, a topical nonsteroidal anti-inflammatory drug is applied to the skin surface of the injured area, and massage is used to promote percutaneous penetration. After waiting for the predetermined penetration time, interferential current therapy is performed. During the treatment, at least two sets of electrodes are arranged in a cross pattern so that the cross electric field covers the target recovery area.

[0027] Interferential electrotherapy utilizes the alternating electric field generated by interferential electricity to achieve the ion electroosmosis effect, promoting the penetration of topical nonsteroidal anti-inflammatory drugs into deep tissues, thus forming a synchronous and synergistic effect between physical analgesia and drug anti-inflammatory targets.

[0028] Preferably, the predetermined permeation time is 2 min–10 min.

[0029] S4. Dynamic parameter adjustment of objective indicators: Monitor ultrasound images, body surface temperature and functional indicators in a 24h-72h cycle, adjust interference electrical parameters and drug regimens according to preset trigger conditions, and dynamically switch and optimize modulation frequency, current intensity and drug dosage / frequency.

[0030] Specifically, during the rehabilitation process, the interference electrical parameters and medication regimen are dynamically adjusted based on objective indicators monitored periodically. This invention establishes a dynamic parameter adjustment system based on objective indicators such as ultrasound imaging, surface infrared thermometry, surface electromyography, and joint function to achieve phased, differentiated, and individualized precise rehabilitation.

[0031] The parameter switching conditions for acute soft tissue injury are: the local body surface temperature decreases by more than 0.5℃ compared with the pretreatment temperature, and ultrasound shows that the edema area has shrunk; the modulation frequency is adjusted from 80Hz–120Hz to 30Hz–80Hz.

[0032] For chronic overuse injuries, when the tissue thickness shown by ultrasound is reduced by more than 10% compared to the initial value, a dynamic frequency sweep mode is superimposed on the original modulation frequency; the frequency sweep range is 10Hz–100Hz, and the frequency sweep period is 1s–3s.

[0033] S5. Multi-dimensional efficacy assessment and treatment plan optimization: Quantify efficacy by comprehensively considering subjective scores, objective indicators, and functional data to optimize and consolidate treatment plans.

[0034] Objective indicators include at least one of the following: imaging indicators and local physiological indicators. Specifically, at least one of the following: tissue thickness, edema area, fluid volume obtained by ultrasound, surface infrared thermometry data, surface electromyography data, joint circumference, and muscle strength test data.

[0035] By comprehensively evaluating subjective pain scores and objective indicators from multiple dimensions, the objectivity and accuracy of the assessment are improved.

[0036] Furthermore, the imaging examination in step S1 uses musculoskeletal ultrasound to measure the edema area, tissue thickness, fluid volume, and cyst wall thickness; the measurement of local physiological indicators includes body surface infrared thermometry, limb circumference measurement, and joint range of motion measurement.

[0037] Furthermore, in step S2, the carrier frequency for the acute soft tissue injury is 2000Hz-6000Hz, the modulation frequency is 80Hz-120Hz, and the current intensity is 5mA-30mA; the modulation frequency for the chronic strain injury is 30Hz-80Hz; and the parameters for the postoperative rehabilitation injury are adjusted in a three-stage gradient.

[0038] Further, the topical nonsteroidal anti-inflammatory drug in step S2 is diclofenac diethylamine cream (preferably with a concentration of 1%-2%), flurbiprofen gel patch, or ketoprofen transdermal patch; after application, it should be left to stand for 2-10 minutes, and the application area should extend 1-3 cm beyond the edge of the damaged area.

[0039] Furthermore, in step S3, the center of the cross arrangement of the two sets of electrodes is directly opposite the center of the damaged area, and the interfering electric field completely covers the damaged area and the drug application area.

[0040] Furthermore, the adjustment triggering conditions for the acute soft tissue injury in step S4 are: the body surface temperature decreases by ≥0.5℃ from the baseline and the area of ​​ultrasound edema shrinks, and the modulation frequency is reduced from 80Hz-120Hz to 30Hz-80Hz.

[0041] Furthermore, the adjustment triggering condition for chronic overuse injury in step S4 is: the tissue thickness is reduced by ≥10% compared to the baseline, and a dynamic frequency sweep mode of 10Hz-100Hz is superimposed, with a frequency sweep period of 1s-3s.

[0042] Furthermore, step S4 divides postoperative rehabilitation damage into three stages, including:

[0043] Phase 1: Acute edema stage, modulation frequency 30Hz–50Hz, current intensity ≤10mA, external transdermal patch, change every 24 hours;

[0044] Phase 2: Functional recovery period. After the edema subsides and the incision heals, the modulation frequency is increased to 80Hz–100Hz, combined with surface electromyography biofeedback, and topical cream is used after training.

[0045] Phase 3: Functional enhancement phase. A dual-channel approach is used to apply differentiated frequency stimulation to antagonistic muscle groups. Parameters are adjusted based on muscle strength and joint stability, and medication is switched to preventative use after training.

[0046] Furthermore, the adjustment of interference electrical parameters according to preset triggering conditions in step S4 includes: the single increase in current intensity ≤ 5mA, and the increase time point is 3min-8min after the start of treatment.

[0047] Furthermore, step S4 also includes: 3-8 minutes after the start of rehabilitation treatment, gradually increasing the current intensity by no more than 5mA per cycle according to the patient's tolerance, and immediately reverting if discomfort occurs.

[0048] Furthermore, the application area of ​​the topical nonsteroidal anti-inflammatory drug extends at least 1 cm beyond the edge of the effective coverage area of ​​the electrode.

[0049] This invention combines the neuro-analgesic and circulation-promoting effects of interfering electrical stimulation with the local anti-inflammatory effects of topical nonsteroidal anti-inflammatory drugs in the same target area to form a synergistic effect that is time-synchronized, spatially overlapping, and mechanistically complementary. At the same time, it constructs a complete rehabilitation treatment process that is phased, quantifiable, and dynamically adjustable, effectively solving the current difficulties in rehabilitation of training injuries.

[0050] The present invention also provides a computer-readable storage medium having a computer program stored thereon, which, when executed by a processor, implements the steps of the training injury phased rehabilitation method described above, which combines interferential current with topical nonsteroidal anti-inflammatory drugs.

[0051] The present invention also provides a computer device, the computer device including a memory, a processor and a computer program stored in the memory and executable on the processor, wherein when the processor executes the program, it implements the steps of the training injury phased rehabilitation method as described above, which combines interferential current with topical nonsteroidal anti-inflammatory drugs.

[0052] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0053] The present invention provides a phased rehabilitation method for training injuries that combines interferential current with topical nonsteroidal anti-inflammatory drugs. This method is based on a synergistic mechanism of electric field and drug penetration, where drug penetration is followed by electric field-enhanced penetration. It utilizes an alternating electric field to enhance iontophoresis and increase drug concentration in deeper tissues. The simultaneous action of electrical stimulation for analgesia and drug anti-inflammation results in significantly better efficacy than single treatment. Initial parameters are set according to acute, chronic, and postoperative classifications, accurately matching the pathological process in stages to achieve optimal matching of phased goals for analgesia, swelling reduction, repair, and functional reconstruction, thus addressing the shortcomings of traditional fixed-parameter treatments. Quantifiable indicators such as ultrasound, temperature, electromyography, and circumference are used for adjustment, replacing experience-based decision-making. Objective indicators drive dynamic adjustments, achieving personalized, adaptive, and repeatable precision treatment. The unified framework of this method is compatible with acute injuries, chronic strain injuries, and postoperative rehabilitation scenarios, exhibiting strong clinical versatility and broad coverage. It can be directly applied to standardized rehabilitation of training injuries and is suitable for the entire cycle of precise rehabilitation for acute soft tissue injuries, chronic strain injuries, and postoperative functional reconstruction caused by military training, competitive sports, and daily fitness activities. Attached Figure Description

[0054] Various other advantages and benefits will become apparent to those skilled in the art upon reading the following detailed description of preferred embodiments. The accompanying drawings are for illustrative purposes only and are not intended to limit the invention.

[0055] In the attached diagram:

[0056] Figure 1 This is a flowchart illustrating the overall treatment process according to an embodiment of the present invention;

[0057] Figure 2 This is a schematic diagram of the cross-arrangement of electrodes in an application example (acute muscle strain) of the present invention.

[0058] Figure 3 This is a schematic diagram of the staged treatment parameter adjustment for chronic tendinitis (Achilles tendon) in Example 2 of the present invention;

[0059] Figure 4 This is a schematic diagram showing the timeline and parameter changes of the three-stage rehabilitation after anterior cruciate ligament reconstruction, which is an application example of the present invention. Detailed Implementation

[0060] Exemplary embodiments will now be described in detail, examples of which are illustrated in the accompanying drawings. When the following description relates to the drawings, unless otherwise indicated, the same numerals in different drawings denote the same or similar elements. The embodiments described in the following exemplary embodiments do not represent all embodiments consistent with this disclosure. Rather, they are merely examples of systems and products consistent with some aspects of this disclosure as detailed in the appended claims.

[0061] The terminology used in this disclosure is for the purpose of describing particular embodiments only and is not intended to be limiting of the disclosure. The singular forms “a,” “the,” and “the” as used in this disclosure and the appended claims are also intended to include the plural forms unless the context clearly indicates otherwise. It should also be understood that the term “and / or” as used herein refers to and includes any and all possible combinations of one or more of the associated listed items.

[0062] It should be understood that although the terms first, second, third, etc., may be used in this disclosure to describe various information, such information should not be limited to these terms. These terms are used only to distinguish information of the same type from one another. For example, without departing from the scope of this disclosure, first information may also be referred to as second information, and similarly, second information may also be referred to as first information. Depending on the context, the word "if" as used herein may be interpreted as "when," "when," or "in response to determination."

[0063] The embodiments of the present invention will be described in further detail below.

[0064] Example

[0065] This invention provides a phased rehabilitation method for training injuries that combines interferential current therapy with topical nonsteroidal anti-inflammatory drugs (NSAIDs). The method comprises five core modules: baseline injury assessment and classification, phased initial parameter setting, drug pretreatment and electric field synergistic therapy, dynamic adjustment of objective indicators, and multi-dimensional efficacy evaluation and program optimization. The entire process follows the principles of "drug penetration first, followed by electric field synergy, phased adaptation, and quantitative regulation," constructing a closed-loop rehabilitation system covering acute injuries, chronic strain, and postoperative rehabilitation. Specifically, it includes the following steps:

[0066] S1. Baseline assessment and classification of injury: Conduct multidimensional baseline assessment of patients, establish a pre-treatment basic database, and provide a basis for classification and parameter setting;

[0067] The assessment includes: injury history taking, physical examination, subjective pain rating, imaging examination, measurement of local physiological parameters, and assessment of limb function;

[0068] The injury history should clearly state the time of injury, the mechanism of injury, the number of recurrences, and the history of previous treatments; the physical examination should clearly state the location of tenderness, the extent of swelling, the range of joint mobility, muscle strength, and special signs (such as the painful arc sign, resisted pain, and drawer test).

[0069] Subjective pain scores were calculated using the VAS visual analog scale or the NRS digital pain scale to quantify rest pain, movement pain, and night pain.

[0070] Imaging examinations are preferably musculoskeletal ultrasound, and MRI and X-rays are used when necessary to measure objective indicators such as the depth of injury, tissue thickness, edema area, fluid volume, fibrous continuity, calcifications, and cyst wall thickness.

[0071] Local physiological indicators include surface infrared thermometry, limb circumference, and degree of swelling; functional assessments include range of motion (ROM), isokinetic muscle strength, single-leg hop distance, and functional scales (AOFAS, Lysholm, UCLA, DASH).

[0072] Based on the assessment results, the injuries are classified into three categories:

[0073] ① Acute soft tissue injury: The course of the disease is ≤72 hours, with inflammation, edema and severe pain as the core characteristics, including muscle strain, ligament sprain, joint contusion and soft tissue crush injury;

[0074] ② Chronic strain injury: The course of the disease is ≥4 weeks, with tissue degeneration, hyperplasia, chronic inflammation and recurrent pain as the core characteristics, including chronic tendinitis, fatigue periostitis, chronic bursitis and tendon insertion inflammation;

[0075] ③ Postoperative rehabilitation and injury: After ligament reconstruction, tendon repair, and arthroscopy, the core characteristics are postoperative edema, incision reaction, muscle atrophy, and functional impairment. It is divided into the acute edema period, the functional recovery period, and the functional strengthening period.

[0076] S2. Initial setting of phased treatment parameters: Based on the injury type, pathological stage, injury location, tissue thickness, and patient tolerance, the parameters for interferential current therapy and the parameters for the use of topical nonsteroidal anti-inflammatory drugs are set differently to achieve a one-injury-one-policy and phased adaptation.

[0077] Interference electrotherapy parameters include: carrier frequency, modulation frequency, current intensity, single treatment time, number of electrode groups, arrangement method, output mode, and on / off ratio;

[0078] Topical medication parameters include: drug type, dosage form, concentration, single dose, frequency of use, application area, and duration of action;

[0079] The parameter setting rules are as follows:

[0080] ① Acute injury parameters (analgesia-swelling reduction priority)

[0081] Carrier frequency: 2000Hz-6000Hz, preferably 4000Hz;

[0082] Modulation frequency: 80Hz-120Hz, preferably 100Hz, activates the spinal cord gate control mechanism, quickly blocks pain transmission, and inhibits neurogenic inflammation;

[0083] Current intensity: 5mA-30mA, adjusted according to the location: 15mA-25mA for areas with abundant muscle in the limbs, and 5mA-15mA for superficial areas;

[0084] Single treatment time: 15-30 minutes, preferably 20 minutes;

[0085] Output mode: continuous modulation mode, on / off ratio 1:1;

[0086] Objectives: Rapid analgesia, control of acute inflammation, elimination of tissue edema, and improvement of local circulation.

[0087] ② Chronic strain parameters (repair-relaxation priority)

[0088] Carrier frequency: 2000Hz-6000Hz, preferably 5000Hz;

[0089] Modulation frequency: 30Hz-80Hz, preferably 50Hz, promotes local blood circulation and lymphatic return, improves tissue hypoxia, accelerates the excretion of metabolic products, and promotes collagen tissue repair;

[0090] Current intensity: 5mA-25mA, superficial areas (Achilles tendon, subacromial) 8mA-12mA, areas with abundant muscle 15mA-20mA;

[0091] Single treatment time: 15-30 minutes, preferably 20 minutes;

[0092] Output mode: Rhythm modulation mode, power on for 5 seconds, power off for 5 seconds, to avoid tissue fatigue;

[0093] Objectives: Relieve chronic pain, improve tissue stiffness, promote the repair of degenerated tissues, and reduce recurrence.

[0094] ③ Postoperative rehabilitation parameters (safety-gradual approach preferred)

[0095] Postoperative rehabilitation is divided into three stages, with parameters gradually increasing from low to high, as follows:

[0096] Phase 1 (acute edema period, 0-2 weeks postoperatively): Modulation frequency 30Hz-50Hz, current intensity ≤10mA, low-intensity stimulation, avoid incision traction and aggravation of edema;

[0097] Phase 2 (functional recovery period, 3-6 weeks post-surgery): The modulation frequency is increased to 80Hz-100Hz, muscle re-education modes are added, and biofeedback is used in conjunction with it.

[0098] Phase 3 (Functional Enhancement Period, 7-12 weeks post-surgery): Dual-channel differential stimulation, applying high-frequency and low-frequency stimulation to antagonistic muscle groups respectively, to enhance muscle strength and coordination.

[0099] The selection criteria for topical nonsteroidal anti-inflammatory drugs are as follows: diclofenac diethylamine cream (concentration 1%-2%), flurbiprofen gel patch, and ketoprofen transdermal patch are preferred.

[0100] Acute injury and acute phase of chronic strain: Choose cream, which is convenient to apply and has a fast effect, 2-4 times a day;

[0101] During the stable phase of chronic strain injury and the postoperative edema phase: Transdermal patches are recommended for their long-lasting effect and should be changed every 24 hours.

[0102] Dosage: For creams, apply 2g / 10cm² based on the affected area, ensuring even coverage; extend the application area 1cm-3cm beyond the edge of the affected area.

[0103] S3. Synergistic therapy of drug pretreatment and electric field:

[0104] Step S3 is a crucial step in this invention, breaking through the limitations of traditional simple combinations to achieve a dual effect of active permeation promotion by the electric field and the target area. Specifically, it includes:

[0105] ① Skin pretreatment: Clean the damaged skin area, remove oil, sweat, and dirt, keep the skin dry and intact, and avoid broken skin, rashes, and scars that may affect drug penetration and electrode contact;

[0106] ② Drug application and initial penetration: Apply the topical nonsteroidal anti-inflammatory drug evenly to the damaged area and the pre-set electrode coverage area, and gently massage for 1-3 minutes to allow the drug to initially penetrate the stratum corneum; leave it to stand for 2-10 minutes, preferably 5 minutes, to allow the drug to form a stable subcutaneous distribution layer and complete the initial transdermal penetration;

[0107] ③ Cross-arrangement of electrodes: Two sets of electrodes are arranged in a cross shape, with the intersection of the line connecting the centers of the electrodes facing the center of the damaged area to ensure that the cross-interference electric field completely covers the damaged area and the drug application area; the electrode spacing is adjusted according to the damaged area to ensure uniform distribution of the electric field.

[0108] ④Activation of electric field synergistic therapy: The interferential current therapy device is activated and treatment is carried out according to the preset parameters. The ion electroosmosis effect and the stratum corneum lipid structure remodeling effect are generated by the medium-frequency alternating electric field, which drive the drug molecules to penetrate the skin barrier and penetrate into deep tissues such as muscles, tendons, ligaments, and bursae in a targeted manner.

[0109] Electric field synergistic mechanism: Alternating electric field changes the arrangement of lipid bilayer in stratum corneum, forming temporary hydrophilic channels and reducing osmotic resistance; it generates a directional driving force for charged drug molecules, increasing the penetration speed and depth; it enables the drug to maintain an effective concentration in deep damaged tissues, and acts on the target area in sync with the interference electrophysical stimulation, achieving a dual synergistic effect of physical analgesia and drug anti-inflammatory.

[0110] S4. Dynamic parameter adjustment based on objective indicators: During the rehabilitation process, objective quantitative indicators are collected in a 24-72 hour monitoring cycle as the sole trigger for parameter adjustment, avoiding subjective experience bias and achieving adaptive optimization of the treatment plan.

[0111] The objective indicators for monitoring include:

[0112] ① Imaging indicators: Musculoskeletal ultrasound measurement of edema area, tissue thickness, fluid volume, cyst wall thickness, and fiber continuity;

[0113] ② Physiological indicators: body surface infrared temperature, limb circumference, skin impedance;

[0114] ③ Functional indicators: joint range of motion, muscle strength, muscle activation (surface electromyography, sEMG);

[0115] ④ Safety indicators: skin reaction, patient tolerance, and discomfort symptoms;

[0116] The dynamic adjustment rules include:

[0117] ① Rules for managing acute injuries:

[0118] Triggering conditions: Local body surface temperature decreases by ≥0.5℃ from baseline, and the area of ​​edema shrinks from baseline according to ultrasound.

[0119] Adjustments: The modulation frequency has been reduced from 80Hz-120Hz to 30Hz-80Hz, and the treatment mode has been changed from "analgesia priority" to "repair priority".

[0120] Current intensity adjustment: After 3-8 minutes from the start of treatment, gradually increase the current by ≤5mA / time. If the patient experiences soreness, stinging, or skin redness, immediately return the current intensity to the previous safe level.

[0121] Medication adjustment: After the edema subsides, reduce the frequency from 3 times a day to 2 times a day, and maintain this until the tissue repair is complete.

[0122] ② Rules for adjusting chronic strain injuries:

[0123] Triggering conditions: Ultrasound shows that the tissue thickness has decreased by ≥10% compared to the baseline, or the tissue stiffness has significantly improved;

[0124] Adjustments: A dynamic frequency sweep mode is superimposed on the original modulation frequency, with a sweep range of 10Hz-100Hz and a sweep period of 1s-3s, to simulate the natural muscle contraction rhythm and improve tissue repair.

[0125] Medication adjustment: Gradually reduce from 3 times a day to 1 time a day, switch to maintenance dose, and prevent relapse.

[0126] ③ Postoperative rehabilitation adjustment rules

[0127] Triggering conditions for edema phase → recovery phase: good incision healing, no exudation or redness, and limb circumference difference (affected side - healthy side) < 2cm;

[0128] Adjustments include: increasing the modulation frequency to 80Hz-100Hz, adding a muscle retraining mode, and switching the medication from a patch to a cream for immediate application after training.

[0129] Recovery phase → Intensive phase triggering conditions: Isokinetic muscle strength on the affected side / unaffected side ≥70%, single-leg jump distance ratio ≥85%, and joint stability meeting the standard;

[0130] Adjustments include: implementing dual-channel differential stimulation, using 80Hz-100Hz for agonist muscles such as the quadriceps and 30Hz-50Hz for antagonist muscles such as the hamstrings, to achieve muscle strength balance reconstruction; and switching medication to preventative use after training.

[0131] S5. Multi-dimensional efficacy assessment and treatment plan optimization: After the treatment cycle, a three-dimensional assessment system encompassing subjective, objective, and functional aspects is constructed to comprehensively quantify the rehabilitation effect.

[0132] ①Subjective assessment: pain score (VAS / NRS), sleep impact, and daily living ability;

[0133] ② Objective assessment: ultrasound imaging indicators (edema, thickness, effusion), body surface temperature, limb circumference;

[0134] ③ Functional assessment: joint range of motion, muscle strength, jump distance, and professional functional scales;

[0135] By comparing data before and after treatment, the improvement rate of indicators is calculated, and a rehabilitation report is generated. For cases that do not meet the standards, parameters are optimized based on the assessment results, and the patients enter a consolidation treatment cycle to achieve closed-loop rehabilitation.

[0136] The application area of ​​the topical nonsteroidal anti-inflammatory drug extends at least 1 cm beyond the edge of the effective coverage area of ​​the electrode to ensure uniform drug concentration within the electric field zone, avoid insufficient edge penetration, and improve synergistic consistency.

[0137] For acute injuries, a high-frequency analgesia mode is used, which stimulates A-β nerve fibers to quickly activate spinal cord gate control, block the transmission of pain signals, and promote the release of endorphins to achieve immediate analgesia. For chronic strain injuries, a medium- and low-frequency repair mode is used, which focuses on improving microcirculation, increasing local blood supply, promoting inflammation absorption and collagen synthesis, and accelerating tissue repair.

[0138] The interfering electrodes are arranged in a cross-shaped symmetrical pattern, with two sets of electrodes placed along the long and short axes of the limb, respectively. The center of the cross coincides with the center of the injury, maximizing the intensity of the deep interfering electric field and ensuring the most precise coverage, thereby improving the synergistic efficiency of the electric field and the drug.

[0139] During dynamic parameter adjustment, the current intensity is increased by ≤5mA per cycle, with an interval of ≥3min, to ensure patient tolerance and treatment safety, and to avoid muscle spasms and skin tingling caused by sudden current changes.

[0140] Figure 1 The basic process of the five steps from S1 to S5 and the damage type judgment branch are shown.

[0141] This invention is based on the principle of enhanced penetration through electric fields. The interfering electric field, operating at a medium frequency, penetrates the skin barrier through a dual action of iontophoresis and stratum corneum remodeling, increasing the penetration depth of topical nonsteroidal anti-inflammatory drugs (NSAIDs) by more than three times. This significantly increases the drug concentration in deep tissues, solving the problems of superficial ineffectiveness and insufficient deep penetration of topical medications. The interfering electric field provides rapid analgesia, improves circulation, and promotes repair; the topical medication provides targeted anti-inflammatory and sustained analgesia. Both work simultaneously in the same target area, creating a triple-effect of analgesia, anti-inflammation, and repair, far superior to single-treatment methods. Differentiated parameters are set for different pathological stages: rapid pain and swelling control in the acute phase, repair of degenerated tissue in the chronic phase, and safe and gradual functional reconstruction in the postoperative phase. This staged pathological adaptation avoids insufficient treatment or aggravated damage caused by a "one-size-fits-all" approach. Using ultrasound, temperature, electromyography, and functional indicators as adjustment criteria, a clear trigger threshold is established, enabling real-time adaptive optimization of the treatment plan as tissue repair progresses, significantly improving accuracy and standardization. It unifies three major scenarios: acute soft tissue injury, chronic overuse injury, and postoperative rehabilitation injury, and forms a standardized operating procedure, which is applicable to clinical applications in multiple scenarios such as military training injuries, sports injuries, and orthopedic rehabilitation.

[0142] Application examples

[0143] The phased rehabilitation method for training injuries based on the synergistic effect of interfering electrical activity and topical nonsteroidal anti-inflammatory drugs of the present invention includes the following specific application examples in practical applications:

[0144] Application Example 1: Acute muscle strain (Grade II quadriceps strain):

[0145] Step S1, Damage Assessment and Classification:

[0146] A comprehensive physical examination was performed on the patient, and the injury history was collected. The injury type was determined to be an acute muscle strain (quadriceps femoris). Ultrasound imaging confirmed the injury as a grade II muscle strain, with local edema and inflammation. The initial edema area was recorded (approximately 6.8 cm² under ultrasound), and the local surface temperature was 38.2℃ (measured with an infrared thermometer). The patient's baseline pain score was recorded as 7 points using the Visual Analogue Scale (VAS). Injury type classification: Acute injury. Step S2: Determining treatment parameters:

[0147] Based on the pathological characteristics of acute muscle strain (primarily acute inflammatory response, requiring priority analgesia), the initial parameters for interferential current therapy were set as follows: carrier frequency 4000Hz, modulation frequency 100Hz (analgesia priority mode, activating A-β fibers to block pain transmission), initial current intensity 15mA, single treatment time 20 minutes, once daily for 10 consecutive days. A 1% diclofenac diethylamine cream was selected, with a single application dose of 2g, three times daily (one of which was used in conjunction with interferential current therapy).

[0148] Step S3, synergistic combination therapy (e.g.) Figure 2 (as shown)

[0149] Cleanse the affected skin and apply 2g of diclofenac diethylamine cream evenly to the quadriceps muscle injury area. Gently massage for about 2 minutes to promote initial transdermal penetration, and wait 5 minutes. Then press the applicator... Figure 2 As shown, one pair each of A-path electrodes (11, 12) and B-path electrodes (13, 14) are arranged in a cross pattern around the injured area (20), ensuring that the cross electric fields (21, 22) of A-path and B-path electrodes cover the entire edema and pain area. Interferential electrotherapy is initiated, and the alternating electric field generated by the interferential electrotherapy further exerts the iontophoresis effect in the drug penetration area, promoting the penetration of residual drug molecules into the deep muscle tissue.

[0150] Step S4, Dynamic Parameter Adjustment:

[0151] Five minutes after the start of treatment, the current intensity was gradually increased from 15mA to 18mA based on the patient's tolerance (amplitude 3mA, not exceeding 5mA / session limit). At the tenth minute, mild local skin redness and rhythmic muscle contraction and relaxation were observed. Based on this, the modulation frequency was fine-tuned from 100Hz to 80Hz to maintain the analgesic effect while appropriately increasing the blood flow promoting effect. Two hours after the interferential current therapy ended, the patient was instructed to apply 1g of cream (as per routine medication not used with electrotherapy). On the second day before treatment, the local surface temperature was measured at 37.4℃ (a decrease of 0.8℃ from the initial value of 38.2℃, exceeding the 0.5℃ threshold). Ultrasound examination showed the edema area had shrunk to 5.2cm² (significantly smaller than the initial 6.8cm²). This triggered the parameter switching condition in claim 7, adjusting the modulation frequency from analgesia mode (80-120Hz) to tissue repair mode (50Hz) to enhance tissue repair stimulation, while maintaining the same dosage of topical cream.

[0152] Step S5, Efficacy Assessment:

[0153] Immediately after treatment, the VAS score decreased to 4 points, and after 24 hours, it decreased to 3 points. By the end of the 10th day of treatment, the VAS score had decreased to 1 point, and the local surface temperature had recovered to 36.7℃ (close to the contralateral normal value of 36.5℃). Ultrasound examination showed that the edema had largely subsided and the muscle fiber arrangement had improved. Changes in VAS score, local surface temperature (38.2℃→36.7℃), and ultrasound changes in edema area (6.8cm²→approximately 0.5cm²) were used as the criteria for multidimensional efficacy evaluation. The treatment was effective.

[0154] Application Example 2: Chronic strain (chronic Achilles tendinitis):

[0155] Step S1, Damage Assessment and Classification:

[0156] The patient was diagnosed with chronic Achilles tendinitis based on a medical history (4-month course of illness) and physical examination. Ultrasound examination showed an Achilles tendon thickness of 8.2 mm (normal reference range 4-6 mm), and ultrasound elastography indicated increased local tissue stiffness with punctate calcifications. The patient's VAS pain score during daily activities was 5-6, worsening upon waking. Injury type classification: chronic overuse injury.

[0157] Step S2: Determining treatment parameters:

[0158] Targeting the pathological characteristics of chronic inflammation and tissue degeneration (primarily promoting blood circulation and improving tissue metabolism), the initial parameters for interferential current therapy were set as follows: carrier frequency 5000Hz, modulation frequency 50Hz (tissue repair mode), current intensity 12mA, and a rhythmic modulation output mode (on / off ratio 1:1, 5 seconds on / off time). Each treatment session lasted 20 minutes, with one treatment per day for 8 consecutive weeks. A 1% diclofenac diethylamine cream was selected, with an initial dosage of 1.5g three times daily.

[0159] Step S3, Synergistic Combined Treatment:

[0160] Cleanse the Achilles tendon and surrounding skin, apply 1.5g of cream evenly, gently massage for 2 minutes to promote absorption, and wait 8 minutes. (See attached image) Figure 2 As shown, four electrodes are arranged in a crisscross pattern, covering the Achilles tendon and calcaneal attachment area, to initiate interferential electrotherapy. The interferential alternating electric field generates continuous ion electroosmotic drive within the Achilles tendon drug penetration area, promoting the penetration of diclofenac molecules into the Achilles tendon core tissue and compensating for the decreased drug delivery rate caused by insufficient local blood flow (chronic tendinitis is characterized by reduced intra-tissue vasculature).

[0161] Step S4, Dynamic parameter adjustment (e.g.) Figure 3 (as shown)

[0162] Phase 1 (Weeks 1-2, stable observation period):

[0163] Treatment parameters remained unchanged from the initial settings. Ultrasonic elastography was used as the core monitoring method to record baseline Achilles tendon stiffness data, monitored every 3-4 days. Second phase (weeks 3-4, parameter escalation period):

[0164] When ultrasound elastography indicated a decrease in Achilles tendon tissue stiffness compared to the initial value, the modulation frequency was gradually increased from 50Hz to 80Hz; the frequency of topical cream application was reduced to twice daily, and the frequency of interferential current therapy was adjusted to five times per week. Phase Three (Weeks 5-8, Intensive Repair Period):

[0165] When ultrasound examination shows that the Achilles tendon thickness has decreased by more than 10% of the initial value of 8.2 mm (i.e., decreased by more than 0.82 mm, down to below 7.4 mm), the frequency sweeping superposition condition in claim 8 is triggered, and a dynamic frequency sweeping mode is superimposed on the original modulation frequency, with a frequency range of 10 Hz to 100 Hz and a frequency sweeping period of 2 seconds; the frequency of topical medication is further reduced to a maintenance dose of once a day according to the improvement of tissue hardness.

[0166] Step S5, Efficacy Assessment:

[0167] Eight weeks after treatment, ultrasound examination showed that the Achilles tendon thickness had recovered to approximately 6.5 mm, a decrease of 1.7 mm (20.7%) from the initial value of 8.2 mm. Ultrasound elastography indicated that tissue stiffness had returned to near normal, and local calcifications had decreased. Multidimensional efficacy was assessed using the VAS pain score (from 5-6 to 1-2), ultrasound morphological indicators (tissue thickness, elastography stiffness score), and the Ankle and Foot Function Scale (AOFAS). All indicators showed that the treatment was effective.

[0168] Figure 3 It includes a modulation frequency polygon and a tissue thickness trend line.

[0169] Application Example 3: Postoperative Joint Rehabilitation (After Anterior Cruciate Ligament Reconstruction)

[0170] Step S1, Preoperative baseline assessment:

[0171] Preoperative baseline assessments were performed on patients scheduled for anterior cruciate ligament (ACL) reconstruction surgery. Range of motion (ROM: flexion 138°, extension -5°), maximum isokinetic muscle strength of the quadriceps and hamstrings (expressed as affected / unaffected side ratio: quadriceps 78%, hamstrings 82%), VAS resting pain score of 1 / movement pain score of 5, and baseline MRI imaging data were recorded as longitudinal control benchmarks for postoperative rehabilitation assessment. Injury type classification: Postoperative rehabilitation.

[0172] Step S2, Presetting staged treatment parameters:

[0173] Based on the different physiological needs in the three stages after ACL reconstruction surgery, a three-stage interference electrical parameter scheme and a corresponding topical medication scheme are pre-set (see step S4 for details).

[0174] Step S3, Synergistic Combined Treatment:

[0175] During each stage of treatment, the appropriate dosage form of topical nonsteroidal anti-inflammatory drug is first applied to the treatment area and allowed to penetrate (for transdermal patches, apply for more than 8 hours beforehand, and for creams, wait 5 minutes). Then, interferential current therapy is performed on the incision healing area and the electrode coverage area to enhance drug targeting by utilizing the penetration-enhancing effect of the electric field. For specific treatment parameters at each stage, please refer to step S4.

[0176] Step S4, phased dynamic parameter adjustment (e.g.) Figure 4 (as shown)

[0177] Phase 1 (0-2 weeks post-surgery, acute edema period):

[0178] Interference electrical parameters: carrier frequency 4000Hz, modulation frequency 30-50Hz (low frequency, mainly to improve blood circulation and lymphatic return), current intensity ≤10mA (low intensity, to avoid irritating tissues around the unhealed incision), single treatment time 15 minutes, once daily. Topical medication: transdermal patch containing 2% diclofenac, applied around the incision to the inner and outer sides of the joint, changed every 24 hours. Monitoring indicators: joint circumference (the difference in thigh circumference at 15cm above the femoral condyle represents the degree of edema), incision healing status. Second stage (3-6 weeks postoperatively, functional recovery period):

[0179] When joint circumference improves (difference between affected and healthy thigh circumference < 2cm) and the incision heals well (no exudation, no redness or swelling), the second stage begins. The interferential current modulation frequency is increased to 80-100Hz, switching to muscle function re-education mode, with each treatment session extended to 20 minutes. Simultaneously, surface electromyography (sEMG) biofeedback is used to monitor the activation ratio of the quadriceps and hamstring muscles in real time, dynamically adjusting electrode positions and current intensity distribution based on the activation ratio. Topical medication is changed to a 1% diclofenac cream, applied immediately after each exercise session, 2g each time, 1-2 times daily. The frequency of interferential current therapy is adjusted according to the rate of improvement in range of motion (ROM) (based on the weekly increase in ROM angle). (Maintain once daily when ROM improvement is progressing smoothly; increase to twice daily when improvement stagnates). Third stage (7-12 weeks post-surgery, functional enhancement period):

[0180] A dual-channel interference mode is employed. Channel 1 (high frequency, 80-100Hz) covers the quadriceps region to promote muscle strength recovery, while Channel 2 (low frequency, 30-50Hz) covers the hamstring region to promote coordination recovery, applying differentiated frequency stimulation to antagonistic muscle groups. Objective indicators such as isokinetic muscle strength test (a muscle strength ratio of over 70% on the affected side at 60° / s is the stage goal), single-leg jump test (a jump distance ratio of over 85% on the affected side), and joint stability (KT-1000 or Lachman test) guide the fine adjustment of parameters. Topical nonsteroidal anti-inflammatory drugs are switched to post-training preventive use (1g cream, applied after training).

[0181] Step S5, Full-process efficacy assessment:

[0182] By longitudinally comparing various indicators at different time points before and after surgery (2 weeks, 6 weeks, and 12 weeks post-surgery), and using multidimensional objective indicators such as Lysholm knee function score, VAS score, range of motion (ROM), and isokinetic muscle strength test, the overall therapeutic effect of the phased combined rehabilitation program was systematically evaluated, and compared with historical interferential current therapy programs or topical drug programs.

[0183] Application Example 4: Chronic bursitis (subacromial bursitis):

[0184] Step S1, Damage Assessment and Classification:

[0185] The patient presented with chronic shoulder pain for 6 months, characterized by pain in a 60°-120° arc-shaped area during shoulder abduction (positive painful arc sign). MRI confirmed subacromial bursitis. Ultrasound examination showed approximately 3.5 ml of fluid accumulation in the subacromial bursa, with the bursa wall thickened to 3.2 mm (normal reference value ≤2 mm). The VAS score was 4 (for daily activities) and reached 7 during elevation. Injury type classification: Chronic strain (bursitis).

[0186] Step S2: Determining treatment parameters:

[0187] For chronic bursal inflammation (effusion, thickened bursal wall), the primary goals are to reduce effusion and alleviate the inflammatory response of the bursal wall. Initial interferential current treatment parameters are set as follows: carrier frequency 4000Hz, modulation frequency 40Hz (low to mid-frequency, to promote lymphatic drainage and accelerate effusion absorption), current intensity 8mA (increased intensity is correspondingly lower due to the thinner soft tissue coverage in the shoulder area), single treatment time 20 minutes, once daily for 6 consecutive weeks. A 1% diclofenac diethylamine cream is selected, with a single dose of 2g twice daily.

[0188] Step S3, Synergistic Combined Treatment:

[0189] Apply 2g of the cream evenly to the subacromial region (the skin surface on the anterolateral aspect of the acromion), gently massage for 2 minutes, and wait 5 minutes. Based on the anatomical morphology of the subacromial region, arrange the electrodes in a crisscross pattern (A: anterior-posterior shoulder; B: superior-lateral shoulder), ensuring the crossed electric field completely covers the subacromial space, and begin interferential electrotherapy. The interferential alternating electric field drives the iontophoresis of drug molecules, promoting the penetration of diclofenac into the subacromial bursa wall tissue, compensating for the insufficient percutaneous penetration of topical drugs due to the deep location of the bursa.

[0190] Step S4, Dynamic Parameter Adjustment:

[0191] Weeks 1-2 (Stable observation period): Parameters remain stable, and ultrasound is used weekly to check the amount of bursal effusion and the thickness of the bursal wall.

[0192] Weeks 3-4: When ultrasound shows that the amount of fluid has decreased by more than 20% from the initial value (from 3.5ml to below 2.8ml), the trigger parameters are upgraded: the modulation frequency is increased to 60Hz to enhance tissue repair stimulation; the frequency of application of topical cream is maintained twice daily.

[0193] Weeks 5-6: When ultrasound examination shows that the cyst wall thickness has decreased by more than 10% of the initial value of 3.2 mm (i.e., reduced to below 2.9 mm), a dynamic sweep frequency mode (10-100 Hz, sweep frequency cycle of 2 seconds) is added to further promote the recovery of cyst wall fibrosis; the topical medication is reduced to maintenance administration once a day.

[0194] Step S5, Efficacy Assessment:

[0195] Six weeks after treatment, ultrasound examination showed that the bursal effusion volume decreased to approximately 0.8 ml, and the bursal wall thickness recovered to 2.1 mm; the positive area of ​​the painful arc sign decreased, and the VAS score for daily activities decreased to 1 point, and the score for overhead movement decreased to 3 points; the shoulder joint function score (UCLA or DASH scale) significantly improved compared to before treatment. Changes in VAS score, changes in ultrasound imaging indicators, and changes in functional score were used as the basis for multidimensional efficacy assessment.

[0196] The differences between this invention and existing technologies (extracorporeal shock wave therapy + topical diclofenac combined treatment) and their corresponding technical effects are shown in Table 1 below:

[0197] Table 1

[0198]

[0199] The combined technology of this invention differs fundamentally from existing technologies in terms of technical principles. It transforms the approach from "physical and pharmaceutical effects acting independently" to "actively driving drug penetration using the electric field effect of physical therapy, forming a dual-mechanism synergy in the target area, thus filling a gap in the field of sports injury rehabilitation."

[0200] This invention utilizes an electric field to actively promote penetration, enhancing the bioavailability of drug molecules to reach deep target tissues. The synergistic effect of physical and drug therapy significantly improves analgesia, anti-inflammation, swelling reduction, and repair, shortening the rehabilitation cycle by more than 30%. It not only alleviates symptoms but also focuses on tissue repair and functional reconstruction, improving the condition of damaged tissues, reducing sexual pain and the risk of recurrent injury, and significantly lowering the recurrence rate. Phased parameters are adapted to different pathological states, and objective indicators are quantitatively controlled to avoid overstimulation and ineffective treatment. Local medication results in extremely low systemic side effects and high safety. A standardized process for assessment, setting, coordination, adjustment, and evaluation is established, ensuring standardized, replicable, and easily promoted operations, overcoming the problems of clinical experience-based and fragmented approaches. It covers all types of training injuries, including acute muscle strains, chronic tendinitis, fatigue periostitis, bursitis, and postoperative rehabilitation, and is applicable to various scenarios such as military, sports, orthopedics, and rehabilitation medicine.

[0201] The technical solution of the present invention has been described above with reference to the preferred embodiments shown in the accompanying drawings. However, it will be readily understood by those skilled in the art that the scope of protection of the present invention is obviously not limited to these specific embodiments. Without departing from the principles of the present invention, those skilled in the art can make equivalent changes or substitutions to the relevant technical features, and the technical solutions after these changes or substitutions will all fall within the scope of protection of the present invention.

[0202] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

Claims

1. A method for the rehabilitation of training injuries in the sub-acute phase, synergistic with the use of external non-steroidal anti-inflammatory drugs, characterized in that, Includes the following steps: S1. Conduct physical examinations, pain scores, imaging examinations, and local physiological index measurements on patients to classify injuries into three categories: acute soft tissue injuries, chronic strain injuries, and postoperative rehabilitation injuries. S2. Based on the type of injury and the pathological stage, differentiate the carrier frequency, modulation frequency, current intensity of the interference current, as well as the dosage form, single-use dose, and frequency of use of the topical nonsteroidal anti-inflammatory drug. S3. First, apply the medication and massage it in to allow it to sit and complete the initial penetration. Then, use two sets of electrodes arranged in a cross shape to implement interferential current therapy. Use the alternating electric field to drive the deep penetration of the medication and form a physical-drug target synergy. S4. Monitor ultrasound images, body surface temperature, and functional indicators in a 24-72 hour cycle, adjust interference electrical parameters and drug regimens according to preset trigger conditions, and dynamically switch and optimize modulation frequency, current intensity, and drug dosage / frequency. S5. Quantify the therapeutic effect by comprehensively considering subjective scores, objective indicators, and functional data to optimize and consolidate the treatment plan.

2. The method of claim 1, wherein the training injury sub-phase rehabilitation method is synergistic with an external non-steroidal anti-inflammatory drug. The imaging examination in step S1 uses musculoskeletal ultrasound to measure the edema area, tissue thickness, fluid volume, and cyst wall thickness; the measurement of local physiological indicators includes body surface infrared thermometry, limb circumference, and joint range of motion.

3. The method for staged rehabilitation of training injuries using interferential current and topical nonsteroidal anti-inflammatory drugs in synergy according to claim 1, characterized in that, In step S2, the carrier frequency for the acute soft tissue injury is 2000Hz-6000Hz, the modulation frequency is 80Hz-120Hz, and the current intensity is 5mA-30mA; the modulation frequency for the chronic strain injury is 30Hz-80Hz; and the parameters for the postoperative rehabilitation injury are adjusted in three stages.

4. The method for staged rehabilitation of training injuries using interferential current and topical nonsteroidal anti-inflammatory drugs in synergy according to claim 1, characterized in that, The topical nonsteroidal anti-inflammatory drug mentioned in step S2 is diclofenac diethylamine cream, flurbiprofen gel patch, or ketoprofen transdermal patch; after application, leave it to stand for 2-10 minutes, and the application area extends 1-3 cm beyond the edge of the damaged area.

5. The method for staged rehabilitation of training injuries using interferential current and topical nonsteroidal anti-inflammatory drugs in synergy according to claim 1, characterized in that, In step S3, the cross center of the two sets of electrodes is directly opposite the center of the damaged area, and the interfering electric field completely covers the damaged area and the drug application area.

6. The method for staged rehabilitation of training injuries using interferential current and topical nonsteroidal anti-inflammatory drugs in synergy according to claim 1, characterized in that, The adjustment triggering conditions for the acute soft tissue injury in step S4 are: the body surface temperature decreases by ≥0.5℃ from the baseline and the area of ​​ultrasound edema decreases, and the modulation frequency is reduced from 80Hz-120Hz to 30Hz-80Hz.

7. The method for staged rehabilitation of training injuries using interferential current and topical nonsteroidal anti-inflammatory drugs in synergy according to claim 1, characterized in that, The adjustment trigger condition for chronic overuse injury in step S4 is: the tissue thickness is reduced by ≥10% compared to the baseline, and a dynamic frequency sweep mode of 10Hz-100Hz is superimposed, with a frequency sweep period of 1s-3s.

8. The method for staged rehabilitation of training injuries using interferential current and topical nonsteroidal anti-inflammatory drugs in synergy according to claim 3, characterized in that, Step S4 divides postoperative rehabilitation into three stages, including: Phase 1: Acute edema stage, modulation frequency 30Hz–50Hz, current intensity ≤10mA, external transdermal patch, change every 24 hours; Phase 2: Functional recovery period. After the edema subsides and the incision heals, the modulation frequency is increased to 80Hz–100Hz, combined with surface electromyography biofeedback, and topical cream is used after training. Phase 3: Functional enhancement phase. A dual-channel approach is used to apply differentiated frequency stimulation to antagonistic muscle groups. Parameters are adjusted based on muscle strength and joint stability, and medication is switched to preventative use after training.

9. The method for staged rehabilitation of training injuries using interferential current and topical nonsteroidal anti-inflammatory drugs in synergy according to claim 1, characterized in that, The adjustment of interference electrical parameters according to preset triggering conditions in step S4 includes: the single increase in current intensity ≤ 5mA, and the increase time point is 3min-8min after the start of treatment.

10. The method for staged rehabilitation of training injuries by synergistic use of interferential current and topical nonsteroidal anti-inflammatory drugs according to claim 1, characterized in that, The application area of ​​the topical nonsteroidal anti-inflammatory drug extends at least 1 cm beyond the edge of the effective coverage area of ​​the electrode.

Images